F. Hoffmann-La Roche Ltd.

History

Year	Detail
1896	Founded in Basel, Switzerland, succeeding Hoffmann, Traub & Co.
1898	Launch of first non-prescription cough syrup "Sirolin".
1925	Business expansion to Japan.
1929	Significant growth in the U.S. with the establishment of manufacturing plants.
1945	Establishment of Pantene Corporation and cosmetic affiliates in Switzerland and the U.S.
1962	Introduction of first anti-cancer drug, Fluorouracil.
1963	Acquisition of Givaudan S.A., a prominent fragrance and flavor manufacturer.
1964	Acquisition of renowned French fragrance company Roure Bertrand Dupont.
1965	Establishment of subsidiaries in India and Mexico.
1968	Inauguration of Roche Institute of Molecular Biology in Nutley, NJ, USA.
1969	Opening of Basel Institute for Immunology in Switzerland.
1986	Corporate restructuring with the formation of Roche Holding AG.
1991	Acquisition of worldwide marketing rights to polymerase chain reaction (PCR).
1998	Acquisition of Boehringer Mannheim, becoming a global leader in diagnostics.
1998	Opening of Roche International Clinical Research Centre in Strasbourg, France.
1999	Launch of Invirase, winning Prix Galien, and Tamiflu for influenza.
2002	Merger with Nippon Roche and Chugai, forming Chugai Pharmaceutical Co., Ltd.
2004	Launch of Avastin, pioneering treatment for metastatic colorectal cancer.
2005	Acquisition of GlycArt Biotechnology, enhancing therapeutic antibody research.
2008	Acquisition of Ventana Inc. in the U.S.
2009	Full ownership of Genentech; Approval of Actemra/RoActemra and cobas 8000 diagnostics system.
2011	Launch of Zelboraf, a breakthrough treatment for skin cancer.
2013	ntroduction of innovative cancer treatments.
2020	Launch of RocheDiabetes Care Platform and first Roche PCR diagnostic test for active infections.
2022	Launch of Vabysmo, the first bispecific antibody for the eye.
2023	Launch of ScreenHer program in Pakistan with Greenstar Social Marketing and The Institute of Human Biology.